<DOC>
	<DOCNO>NCT02360319</DOCNO>
	<brief_summary>The goal project show best possible option prevent relapse patient suffer first episode ( &lt; 1 year anti-psychotic medication ) early phase ( &lt; 5 year lifetime exposure anti-psychotic medication ) schizophrenia enhance medication adherence . The study design answer question whether use long-acting injectable ( LAI ) antipsychotic early course treatment break cycle frequent relapse affect many patient early phase schizophrenia . The participate research site ( individual patient ) randomly assign either medication prescribe treat physician ( restriction ) regimen involve monthly long act injectable antipsychotic . The site assign one one basis either arm take account type patient population geographical area . Patients enrol study participate regular assessment either phone person follow period 2 year . The primary outcome measure time first hospitalization .</brief_summary>
	<brief_title>Comparison Long-acting Injectable Antipsychotic v Clinician 's Choice Early Treatment Break Cycle Relapse Early Phase Schizophrenics</brief_title>
	<detailed_description>Approximately 40 U.S. site participate study order enroll approximately 500 patient year period . They recruit two cohort - first episode cohort early phase ( EP ) cohort , approximately 250 patient cohort . Enrollment patient discontinue appropriate number target cohort reach . After provide write informed consent , patient screen general eligibility clinical team site . Basic demographic data collect determine suitability inclusion study . The site complete information interview comprise data regard symptomology history , diagnosis schizophrenia fall centralize , remote blind rater enable consistency eligibility . Prescribers sit clinician 's choice arm treat patient manner appropriate individual . Prescribers sit Aripiprazole Once Monthly arm monthly prescribe administer medication accord recommendation contain product labeling . For period 2 year subject receive bimonthly call inquire visit emergency room hospitalization . At 4 month interval information use service , insurance status , work , school attendance , service use outcome assess .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Are able provide write informed consent Have confirm diagnosis schizophrenia define Diagnostic Statistical Manual ( DSM ) 5 criterion use SCID ( Structured Clinical Interview DSM disorder ) Are age 18 35 , inclusive Have follow history antipsychotic medication 1 . First episode subject : &lt; 1 year lifetime exposure antipsychotic medication one episode psychosis 2 . EP subject : 1 year 5 year lifetime exposure antipsychotic medication subject &lt; 1 year lifetime antipsychotic medication one episode psychosis . For LAI subject : Must willing accept injectable form treatment Have current primary DSM5 diagnosis schizophrenia , include schizophreniform disorder , schizoaffective disorder , major depressive disorder , bipolar disorder , delirium , dementia , amnestic cognitive disorder . For LAI site know allergy intolerance aripiprazole , past negative response aripiprazole explain nonadherence Be pregnant lactate Have unstable medical condition , opinion investigator , would detrimental subject would confound result study Subjects MRI subset presence metal implant , pacemaker , irremovable prosthetic device , device situation may preclude image</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>First episode recent onset</keyword>
</DOC>